Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000134.xml
Download PDF
Diabetologie und Stoffwechsel 2025; 20(S 02): S319-S324
DOI: 10.1055/a-2592-8500
DOI: 10.1055/a-2592-8500
DDG-Praxisempfehlung
Nephropathie bei Diabetes
Authors
Die DDG-Praxisempfehlungen werden regelmäßig zur zweiten Jahreshälfte aktualisiert. Bitte stellen Sie sicher, dass Sie jeweils die neueste Version lesen und zitieren.
Neuerung 1: Update Nomenklatur für Nierenfunktion und Nierenkrankheiten
Begründung: Positionspapier im Auftrag der nephrologischen Fachgesellschaften in Deutschland, Österreich und der Schweiz
Stützende Quellenangabe: [1]
Neuerung 2: Überblick zur Diagnostik und den daraus resultierenden Maßnahmen bei Menschen mit chronischer Nierenkrankheit
Begründung: Deutsche Übersetzung neuer Leitlinien
Stützende Quellenangabe: [8]
Publication History
Received: 26 June 2025
Accepted: 02 July 2025
Article published online:
24 December 2025
© 2025. Thieme. All rights reserved.
Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
-
Literatur
- 1 Eckardt KU, Binet I, de Groot K. et al. Nomenklatur für Nierenfunktion und Nierenkrankheiten Durch Präzision und Verständlichkeit zu besserer Erfassung und Prognose. Dtsch Med Wochenschr 2022; 147: 1398-1406
- 2 KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 2024; 105: S117-S314
- 3 Marx N, Federici M, Schütt K. et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC). Eur Heart J 2023; 44: 4043-4140
- 4 Mogensen CE. Introduction: Diabetes mellitus and the kidney. Kidney Int 1982; 21: 673-675
- 5 de Boer IH, Khunti K, Sadusky T. et al. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care 2022; 45: 3075-3090
- 6 Chen DC, Potok OA, Rifkin D. et al. Advantages, Limitations, and Clinical Considerations in Using Cystatin C to Estimate GFR. Kidney360 2022; 3: 1807-1814
- 7 Rossing P, Caramori ML, Chan JCN. et al. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int 2022; 102: S1-S127
- 8 Rossing P, Caramori ML, Chan JCN. et al. Kurzfassung der KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (Leitlinie für die klinische Praxis zur Diabetesbehandlung bei chronischer Nierenkrankheit): eine Aktualisierung auf Grundlage neuer Erkenntnisse. Diabetol Stoffwechs 2025; 20: 47-58
- 9 Mancia G, Kreutz R, Brunström M. et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens 2023; 41: 1874-2071
- 10 Cheung AK, Chang TI, Cushman WC. et al. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int 2021; 99: S1-S87
- 11 Davies MJ, Aroda VR, Collins BS. et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2022; 45: 2753-2786
- 12 Gallwitz B, Aberle J, Birkenfeld AL. et al. Therapie des Typ-2-Diabetes. Diabetol Stoffwechs 2025; 20: S193-S210
- 13 Bally L, Gubler P, Thabit H. et al. Fully closed-loop insulin delivery improves glucose control of inpatients with type 2 diabetes receiving hemodialysis. Kidney Int 2019; 96: 593-596
- 14 Boughton CK, Tripyla A, Hartnell S. et al. Fully automated closed-loop glucose control compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis: an open-label, randomized crossover trial. Nat Med 2021; 27: 1471-1476
- 15 Mach F, Baigent C, Catapano AL. et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111-188
- 16 Perkovic V, Jardine MJ, Neal B. et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019; 380: 2295-2306
- 17 Heerspink HJL, Stefánsson BV, Correa-Rotter R. et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020; 383: 1436-1446
- 18 The EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2023; 388: 117-127
- 19 Agarwal R, Filippatos G, Pitt B. et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 2022; 43: 474-484
- 20 Agarwal R, Green JB, Heerspink HJL. et al. Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes. N Engl J Med 2025; 393: 533-543
- 21 Perkovic V, Tuttle KR, Rossing P. et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med 2024; 391: 109-121